Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor. This Phase IIa study assessed the effects of CHF6001 on markers of inflammation in induced sputum and blood in patients with chronic obstructive pulmonary disease (COPD). This was a multicentre, three-period (each 32 days), three-way, placebo...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | angličtina |
| Vydáno: |
2019
|
| On-line přístup: | https://doi.org/10.1186/s12931-019-1142-7 https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-019-1142-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|